Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pembrolizumab in previously treated metastatic castration-resistant prostate cancer
MOH_2017-06-08_000497Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- May 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in prostate cancer (PCa) and metastatic castration-resistant prostate cancer (mCRPC), sponsored by Merck & Co. Started May 2016; status: active, not recruiting.
02
Drugs
03
Conditions
prostate cancer (PCa)metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on MOH_2017-06-08_000497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-06-08_000497.